RAPP Rapport Therapeutics, Inc. Common Stock
Healthcare$39.71+5.28%ClosedMarket Cap: $1.45B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.78
P/S
68.83
EV/EBITDA
-11.08
DCF Value
$0.79
FCF Yield
-5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.5%
Operating Margin
-611.0%
Net Margin
-536.4%
ROE
-24.8%
ROA
-21.6%
ROIC
-25.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $20.0M | 98.9% | $-24.2M | $-19.9M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-38.5M | $-33.8M | $— | — |
| FY null | $0.00 | -Infinity% | $-125.1M | $-111.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-30.0M | $-26.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-29.5M | $-26.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-27.1M | $-24.1M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-23.5M | $-20.0M | $— | — |
| FY null | $0.00 | -Infinity% | $-83.1M | $-78.3M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-21.6M | $-17.5M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-20.8M | $-18.1M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-17.1M | $-22.7M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-14.8M | $-13.5M | $-0.07 | — |